2026-05-07 · semaglutide, ozempic, wegovy, glp-1, prescription-medications

Ozempic vs Wegovy

Ozempic and Wegovy are often discussed as if they were two different drugs, but they share the same active ingredient: semaglutide. Both are once-weekly injections from Novo Nordisk, and both quiet appetite signals through the same gut-hormone pathway. What separates them is what each is approved to treat, how high the dose goes, what insurance will pay for, and how much you might lose on the scale.

Who this is for / not for

Good fit if:

• You are weighing semaglutide as an option for weight management or type 2 diabetes and want to understand which brand applies to you.
• You have insurance coverage questions and need to know why one brand may be approved while the other is not.
• Your clinician has suggested either Ozempic or Wegovy and you want plain-language background before your next visit.

Not a fit if:

• You have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Both medications carry a boxed warning and are contraindicated.
• You have had pancreatitis or severe gastrointestinal disease without clinician clearance.
• You are pregnant, breastfeeding, or planning pregnancy in the near term.
• You want a short-term solution. Semaglutide is a chronic therapy, and stopping is associated with weight regain.

The short answer

Same molecule, different brand. Ozempic is FDA approved for adults with type 2 diabetes. Wegovy is FDA approved for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with a weight-related condition, and for adolescents 12 and older with obesity. Wegovy also reaches a higher maintenance dose (2.4 mg) than Ozempic (max 2.0 mg).

For a broader look at this drug class, see our GLP-1 weight loss overview.

Side-by-side comparison

How they work

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone the small intestine releases after meals, which slows stomach emptying, increases feelings of fullness, and reduces appetite signals in the brain. Because the mechanism is identical between Ozempic and Wegovy, the way the medication feels in your body is the same. The differences come from dose level, indication, and how the drug is studied.

For more on how the drug acts in the body and what to expect during titration, see ozempic for weight loss.

Key differences

1. FDA approval and indication

• Ozempic is approved for adults with type 2 diabetes to improve blood sugar control, and for adults with type 2 diabetes plus established cardiovascular disease to reduce the risk of major cardiovascular events.
• Wegovy is approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Wegovy is also approved for adolescents 12 and older with obesity, and for cardiovascular risk reduction in adults with obesity and known cardiovascular disease.

This distinction matters at the pharmacy counter: insurance plans usually authorize each brand only for its FDA-approved use.

2. Dosing schedule and maximum dose

Both medications use a slow titration designed to limit nausea. Doses step up about every four weeks.

• Ozempic: 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg. The 0.25 mg dose is a starting dose only and is not therapeutic. Most users settle at 1.0 mg or 2.0 mg.
• Wegovy: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg. Maintenance is 2.4 mg, with 1.7 mg available as an alternate maintenance dose if 2.4 mg is not tolerated.

The higher Wegovy dose is a major reason it produces larger average weight loss in trials.

3. Clinical trial results

Trial averages are not promises, but they show what is reasonable to expect.

• Wegovy (STEP 1 trial, NEJM 2021): Adults with overweight or obesity (without diabetes) on 2.4 mg semaglutide lost about 14.9 percent of total body weight at 68 weeks, compared with 2.4 percent on placebo.
• Wegovy (STEP 2 trial, Lancet 2021): Adults with overweight or obesity and type 2 diabetes lost about 9.6 percent on 2.4 mg, compared with 3.4 percent on placebo. (Diabetes generally blunts weight loss with this drug class.)
• Ozempic (SUSTAIN program): Adults with type 2 diabetes on 1.0 mg lost roughly 4 to 6 kg over 30 to 56 weeks. SUSTAIN FORTE (2021) tested 2.0 mg vs 1.0 mg in T2D and showed slightly greater weight loss at the higher dose.

4. Cost and insurance

List prices in the United States hover around $1,000 per month for Ozempic and $1,300 to $1,400 for Wegovy, with significant variation in actual out-of-pocket cost.

• Ozempic is widely covered for type 2 diabetes by commercial plans and Medicare Part D when prescribed for that diagnosis.
• Wegovy coverage for obesity-only indications is patchy. Many plans require BMI documentation, a 6-month record of supervised lifestyle attempts, and prior authorization. Some plans exclude weight-loss drugs entirely.
• Manufacturer savings cards can reduce monthly costs for eligible commercially insured patients. Programs change; confirm current terms with Novo Nordisk.
• Compounded semaglutide is sold by some pharmacies and online clinics. These products are not FDA approved, are not evaluated for the same purity or dosing accuracy as Ozempic or Wegovy, and have been linked to dosing errors and adverse events. The FDA has issued warnings.

For a wider safety lens on this and other prescription weight-loss drugs, see weight loss drug safety and our overview of prescription weight loss medications.

5. Side effects

Because the molecule is the same, the side effect profile is shared. The most common are gastrointestinal: nausea, diarrhea, constipation, vomiting, abdominal pain, and reflux. They tend to be most pronounced during dose escalation and generally improve as the body adjusts. Less common but more serious risks include pancreatitis, gallbladder disease, kidney injury (often from dehydration), hypoglycemia (mainly in people who also take insulin or sulfonylureas), and a boxed warning for thyroid C-cell tumors based on rodent studies.

For a more detailed breakdown, see our guide to ozempic side effects.

Which one is right for you

Use this checklist to focus a conversation with your clinician.

• Do you have type 2 diabetes? If yes, Ozempic is the brand most plans cover, and the 2.0 mg dose can support both glucose control and modest weight loss.
• Is weight loss the primary goal? If yes, Wegovy is the brand that matches the indication and the higher 2.4 mg dose studied for that purpose.
• What does your formulary cover? Call your plan or use its online formulary tool. Ask about prior authorization, BMI thresholds, and step-therapy rules. The answer often decides which brand is realistic.
• Are you considering tirzepatide as well? If your goal is the largest possible average weight reduction, the dual-receptor agonist tirzepatide (Wegovy’s main competitor) has produced larger averages in head-to-head and parallel trials. Compare in detail in our semaglutide vs tirzepatide guide.
• What about Wegovy specifically? For dose schedule, candidacy criteria, and what the first six months typically look like, see our standalone Wegovy weight loss guide.
• Long-term plan. Both brands are chronic therapies. Stopping is associated with regain in trial extension data. Choose what you can sustain. If weight loss slows partway through treatment, our weight loss plateau guide covers what usually breaks a stall before adjusting medication.

Frequently asked questions

How this article was researched

We reviewed the published phase 3 trials for semaglutide in the STEP and SUSTAIN programs (New England Journal of Medicine, JAMA, The Lancet), along with the FDA prescribing information for Ozempic and Wegovy. We focused on peer-reviewed primary evidence for expected weight loss, dosing, indications, and known safety considerations.